Even as it’s moving into the US tobacco alternatives market, Philip Morris International (PMI) may be setting itself up for a future move into the cannabis industry.  The company has reportedly purchased a patent for a genetically modified cannabis plant, and is said to have invested $20m in an Israeli company that makes cannabis inhalers.

Meanwhile, an expert on cannabis and behaviour has told CBD-Intel that reports of 60 people suffering medical ill-effects from vaping products marketed as containing cannabinoid oil suggested symptoms consistent with them having received “tainted product”.

Read full article
I'm already a subscriber
Author default picture

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization